The Sleep Amyloid, Slow WAve Race and Ethnicity Study

NCT03814603 | Completed FDA Drug

• 1 other identifier: s18-01302
• Study Type: observational
• Target: 210
• Locations: 1 country
• Sites: 1

Brief Summary

African-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2).

Conditions

Alzheimer Disease

Outcome Measures

Primary Outcomes (3)

• Association between Percentage of African Ancestry (%AF) and Slow Wave Sleep (SWS) duration and activity (SWA).

  Aim 1 will test if individual % African ancestry (%AF), estimated from 0-100 and computed using a maximum likelihood method for inferring individual admixture based upon allele frequencies ascertained from Utah residents with Northern and Western European ancestry and West African samples, is associated with short SWS duration/ and poor slow wave activity (SWA), determined through polysomnography, in older AAs while controlling for other moderating factors.

  Determined at baseline.

• Examine association between SWS duration and poor SWA with longitudinal change in amyloid burden.

  Aim 2 will test the effect of race and its interaction with baseline SWS duration and SWA with amyloid plaque burden both at baseline and follow-up by determining mean PiB standard uptake value using PET-MR.

  Baseline and 2.5 year follow-up

• Examine the association between race, SWS duration and poor SWA and cognition using both standardized and sleep-dependent cognitive tests at baseline and follow-up.

  Aim 3 will test the effect of race and baseline SWS duration and poor SWA on overall cognition using standardized and sleep-dependent tests: the UDS 3.0, WHICAP Clinical Core Neuropsychological test battery, as well as a 3-D Virtual Maze Task, both at baseline and follow-up.

  Baseline and 2.5 year follow-up

Study Arms (2)

African Americans

Procedure: PET-MR Scan; Drug: PiB

Non-Hispanic Whites

Procedure: PET-MR Scan; Drug: PiB

Interventions

PET-MR Scan PROCEDURE

Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.

African Americans; Non-Hispanic Whites

PiB DRUG

Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.

African Americans; Non-Hispanic Whites

Eligibility Criteria

• Age: 60 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

210 cognitively normal elderly (Clinical Dementia Rating \[CDR\]=0), self-identified as African-American (AA) or non-Hispanic white (NHW), ages 60 to 75 years, with English as their primary language

You may qualify if:

• Male and female subjects with normal cognition and ages 60 to 75.
• Within normal limits on neurological and psychiatric examinations. All subjects enrolled will have a CDR=0.
• An informed family member or life-partner (preferably bed-partner) will be interviewed over the phone or on the first or second visit to confirm the reliability of the subject interview. A study partner is preferably a spouse, close friend, or relative.
• Self-identified as African-American Black or non-Hispanic white.
• All subjects must sign the Alzheimer's Disease Center consent form

You may not qualify if:

• History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
• Significant history of alcoholism based off of the CAGE questionnaire (\>2) or drug abuse.
• History of psychiatric illness (e.g., schizophrenia, bipolar or PTSD)
• Lifelong depression and anxiety will be allowed as long as there has been no active depressive episode within the last two years.
• Geriatric Depression Scale (short form)\>6.
• Insulin dependent diabetes.
• Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions based off of the PI's discretion.
• Physical impairment of such severity as to adversely affect the validity of psychological testing.
• Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
• Medications affecting cognition or SWS:
• Narcotic analgesics.
• Chronic use of medications with anticholinergic activity.
• Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline).
• Others: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, gabapentin, pregabalin, trazodone, cholinesterase inhibitors, memantine.
• Chronic use of antidepressants are allowed.

Sponsors & Collaborators

• NYU Langone Health: lead
• Icahn School of Medicine at Mount Sinai: collaborator

Study Sites (1)

NYU Center for Brain Health

New York, New York, 10016, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood will be drawn for clinical labs and to obtain DNA for ApoE genotyping.

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Ricardo Osorio, MD

  NYU Department of Psychiatry

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 27, 2018
• First Posted: January 24, 2019
• Study Start: November 21, 2018
• Primary Completion: May 31, 2025
• Study Completion: May 31, 2025
• Last Updated: September 22, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (1)